[{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"St. Antonius Hospital | Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Micafungin","moa":"1,3-beta-glucan synthase","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ St. Antonius Hospital | Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Radboud University Medical Center \/ St. Antonius Hospital | Astellas Pharma"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Micafungin","moa":"1,3-beta-glucan synthase","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UT Southwestern Medical Center \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ Astellas Pharma"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"University of Illinois, Chicago","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Illinois, Chicago","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Illinois, Chicago \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Illinois, Chicago \/ Merck & Co"},{"orgOrder":0,"company":"Insel Gruppe AG, University Hospital Bern","sponsor":"Fresenius Kabi AB Brunna","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase 1; Amidophosphoribosyltransferase; Glutamine synthetase","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Insel Gruppe AG, University Hospital Bern","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Insel Gruppe AG, University Hospital Bern \/ Fresenius Kabi AB Brunna","highestDevelopmentStatusID":"11","companyTruncated":"Insel Gruppe AG, University Hospital Bern \/ Fresenius Kabi AB Brunna"},{"orgOrder":0,"company":"Jacobi Medical Center","sponsor":"Cumberland Pharmaceuticals | Sagatech Electronics Inc, Alberta, Canada","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Jacobi Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jacobi Medical Center \/ Cumberland Pharmaceuticals | Sagatech Electronics Inc, Alberta, Canada","highestDevelopmentStatusID":"11","companyTruncated":"Jacobi Medical Center \/ Cumberland Pharmaceuticals | Sagatech Electronics Inc, Alberta, Canada"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"St. Antonius Hospital | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NETHERLANDS","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Posaconazole","moa":"Cytochrome P450 51","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radboud University Medical Center \/ St. Antonius Hospital | Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Radboud University Medical Center \/ St. Antonius Hospital | Merck & Co"},{"orgOrder":0,"company":"University Medical Centre Ljubljana","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SLOVENIA","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Corifollitropin Alfa","moa":"Follicle stimulating hormone receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University Medical Centre Ljubljana","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Centre Ljubljana \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University Medical Centre Ljubljana \/ Merck & Co"},{"orgOrder":0,"company":"St Andrew's Healthcare","sponsor":"Loughborough University","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"St Andrew's Healthcare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"St Andrew's Healthcare \/ Loughborough University","highestDevelopmentStatusID":"11","companyTruncated":"St Andrew's Healthcare \/ Loughborough University"},{"orgOrder":0,"company":"Western University, Canada","sponsor":"London Health Sciences Centre Research Institute (Lawson) | Queen Elizabeth II Health Sciences Centre | St. Michael's Hospital (Toronto, Canada)","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Western University, Canada","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Western University, Canada \/ London Health Sciences Centre Research Institute (Lawson) | Queen Elizabeth II Health Sciences Centre | St. Michael's Hospital (Toronto, Canada)","highestDevelopmentStatusID":"11","companyTruncated":"Western University, Canada \/ London Health Sciences Centre Research Institute (Lawson) | Queen Elizabeth II Health Sciences Centre | St. Michael's Hospital (Toronto, Canada)"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Pennsylvania \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ Novo Nordisk"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | Phenomix Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | Phenomix Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Mayo Clinic \/ National Institutes of Health | National Institute of Diabetes and Digestive and Kidney Diseases | Phenomix Sciences"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mayo Clinic \/ Undisclosed"},{"orgOrder":0,"company":"University of Leicester","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Leicester","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Leicester \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"University of Leicester \/ Novo Nordisk"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Pennsylvania \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ Novo Nordisk"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"UT Southwestern Medical Center \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ Novo Nordisk"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Novo Nordisk"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eli Lilly | National Institute on Minority Health and Health Disparities","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Washington University School of Medicine \/ Eli Lilly | National Institute on Minority Health and Health Disparities","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Eli Lilly | National Institute on Minority Health and Health Disparities"},{"orgOrder":0,"company":"University of Melbourne","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Melbourne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Melbourne \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"University of Melbourne \/ Eli Lilly"},{"orgOrder":0,"company":"Bio Products Laboratory","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Human Normal Immunoglobulin","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Bio Products Laboratory","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Products Laboratory \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bio Products Laboratory \/ Undisclosed"},{"orgOrder":0,"company":"Certmedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Polyglucosamine","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Certmedica","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Certmedica \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Certmedica \/ Undisclosed"},{"orgOrder":0,"company":"Heilpflanzenwohl","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Polyglucosamine Glucomannan","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Heilpflanzenwohl","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"Heilpflanzenwohl \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Heilpflanzenwohl \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Smofkabiven E","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Smoflipid","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Smoflipid","moa":"Homeostasis","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Promomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Promomed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Promomed \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Promomed \/ Undisclosed"},{"orgOrder":0,"company":"New York State Psychiatric Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sibutramine Hydrochloride","moa":"Monoamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"New York State Psychiatric Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New York State Psychiatric Institute \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"New York State Psychiatric Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Ziekenhuis Oost-Limburg","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BELGIUM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"Muscle-type nicotinic acetylcholine receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Ziekenhuis Oost-Limburg","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ziekenhuis Oost-Limburg \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Ziekenhuis Oost-Limburg \/ Merck & Co"},{"orgOrder":0,"company":"University of Missouri-Columbia","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"Muscle-type nicotinic acetylcholine receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Missouri-Columbia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Missouri-Columbia \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Missouri-Columbia \/ Merck & Co"},{"orgOrder":0,"company":"Michelle Cardel, PhD, MS, RD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Michelle Cardel, PhD, MS, RD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Michelle Cardel, PhD, MS, RD \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Michelle Cardel, PhD, MS, RD \/ Undisclosed"},{"orgOrder":0,"company":"New York State Psychiatric Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Phentermine","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"New York State Psychiatric Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New York State Psychiatric Institute \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"New York State Psychiatric Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Alvogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phentermine","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Alvogen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Alvogen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Alvogen \/ Undisclosed"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Johns Hopkins University | Kaiser Permanente | HealthPartners Institute | University of Texas Health Science Center at Houston | Biomedical Research Institute of New Mexico | WW International Inc | KVK.Tech | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phentermine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Forest University Health Sciences \/ Johns Hopkins University | Kaiser Permanente | HealthPartners Institute | University of Texas Health Science Center at Houston | Biomedical Research Institute of New Mexico | WW International Inc | KVK.Tech | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"11","companyTruncated":"Wake Forest University Health Sciences \/ Johns Hopkins University | Kaiser Permanente | HealthPartners Institute | University of Texas Health Science Center at Houston | Biomedical Research Institute of New Mexico | WW International Inc | KVK.Tech | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"The Royal's Institute of Mental Health Research","sponsor":"University of Ottawa | The Royal Ottawa Mental Health Centre | Bausch Health | CHEO Research Institute | LEAF Weight Management Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"The Royal's Institute of Mental Health Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Royal's Institute of Mental Health Research \/ University of Ottawa | The Royal Ottawa Mental Health Centre | Bausch Health | CHEO Research Institute | LEAF Weight Management Clinic","highestDevelopmentStatusID":"11","companyTruncated":"The Royal's Institute of Mental Health Research \/ University of Ottawa | The Royal Ottawa Mental Health Centre | Bausch Health | CHEO Research Institute | LEAF Weight Management Clinic"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Orexigen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Orexigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orexigen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Orexigen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"University of Massachusetts, Worcester","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Mental Health Center \/ University of Massachusetts, Worcester","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Mental Health Center \/ University of Massachusetts, Worcester"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Orexigen Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"NORWAY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ Orexigen Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Oslo University Hospital \/ Orexigen Therapeutics"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Bausch Health","highestDevelopmentStatusID":"11","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Bausch Health"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Bausch Health","highestDevelopmentStatusID":"11","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Bausch Health"},{"orgOrder":0,"company":"Laval University","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laval University \/ Bausch Health","highestDevelopmentStatusID":"11","companyTruncated":"Laval University \/ Bausch Health"},{"orgOrder":0,"company":"Currax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Currax","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Currax \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Currax \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lorcaserin HCl","moa":"Serotonin 2c (5-HT2c) receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lorcaserin HCl","moa":"Serotonin 2c (5-HT2c) receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lorcaserin HCl","moa":"Serotonin 2c (5-HT2c) receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Vivus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"VI-0521","moa":"SGLT1\/SGLT2","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vivus \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Vivus \/ Undisclosed"},{"orgOrder":0,"company":"Vivus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"VI-0521","moa":"SGLT1\/SGLT2","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vivus \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Vivus \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Solution","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Pharmaceutical Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Pharmaceutical Research Institute","highestDevelopmentStatusID":"11","companyTruncated":"University of Copenhagen \/ Pharmaceutical Research Institute"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"McGill University Health Centre Research Institute","sponsor":"McGill University | Asociacion Civil Selva Amazonica | World Health Organization | Thrasher Research Fund | Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Mebendazole","moa":"Tubulin","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"McGill University Health Centre Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"McGill University Health Centre Research Institute \/ McGill University | Asociacion Civil Selva Amazonica | World Health Organization | Thrasher Research Fund | Canadian Institutes of Health Research","highestDevelopmentStatusID":"11","companyTruncated":"McGill University Health Centre Research Institute \/ McGill University | Asociacion Civil Selva Amazonica | World Health Organization | Thrasher Research Fund | Canadian Institutes of Health Research"},{"orgOrder":0,"company":"Laval University","sponsor":"OmniActive Health Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Capsimax","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Laval University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laval University \/ OmniActive Health Technologies","highestDevelopmentStatusID":"11","companyTruncated":"Laval University \/ OmniActive Health Technologies"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Clinolipid","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Clinolipid","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Baxter Healthcare Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Danone Specialized Nutrition","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Fortimel","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Danone Specialized Nutrition","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danone Specialized Nutrition \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Danone Specialized Nutrition \/ Undisclosed"},{"orgOrder":0,"company":"Musclegen Research, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Genepro Protein","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Musclegen Research, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Musclegen Research, Inc. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Musclegen Research, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Kanglaite Pharmaceutical Co.Ltd","sponsor":"H & J CRO International","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Kanglaite","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Zhejiang Kanglaite Pharmaceutical Co.Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang Kanglaite Pharmaceutical Co.Ltd \/ H & J CRO International","highestDevelopmentStatusID":"11","companyTruncated":"Zhejiang Kanglaite Pharmaceutical Co.Ltd \/ H & J CRO International"},{"orgOrder":0,"company":"InQpharm Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Litramine","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"InQpharm Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InQpharm Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"InQpharm Group \/ Undisclosed"},{"orgOrder":0,"company":"Kwang Dong Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Kwang Dong Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kwang Dong Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kwang Dong Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Kwang Dong Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Kwang Dong Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kwang Dong Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kwang Dong Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Cook County Health","sponsor":"Rush University","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Cook County Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cook County Health \/ Rush University","highestDevelopmentStatusID":"11","companyTruncated":"Cook County Health \/ Rush University"},{"orgOrder":0,"company":"Albany College of Pharmacy and Health Sciences","sponsor":"VA Office of Research and Development | Hortense & Louis Rubin Dialysis Center | Satellite Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Albany College of Pharmacy and Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albany College of Pharmacy and Health Sciences \/ VA Office of Research and Development | Hortense & Louis Rubin Dialysis Center | Satellite Healthcare","highestDevelopmentStatusID":"11","companyTruncated":"Albany College of Pharmacy and Health Sciences \/ VA Office of Research and Development | Hortense & Louis Rubin Dialysis Center | Satellite Healthcare"},{"orgOrder":0,"company":"Kunshan First People's Hospital Affiliated to Jiangsu University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Kunshan First People's Hospital Affiliated to Jiangsu University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kunshan First People's Hospital Affiliated to Jiangsu University \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kunshan First People's Hospital Affiliated to Jiangsu University \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Amit.Pai","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Merck & Co \/ Amit.Pai","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Amit.Pai"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Manjunath Prakash Pai","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tigecycline","moa":"Bacterial 70S ribosome","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Manjunath Prakash Pai","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Manjunath Prakash Pai"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Pedro Paulo Tanaka","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Propofol","moa":"GABA-A receptor; anion channel","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxter Healthcare Corporation \/ Pedro Paulo Tanaka","highestDevelopmentStatusID":"11","companyTruncated":"Baxter Healthcare Corporation \/ Pedro Paulo Tanaka"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ingrid Jazet","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Exenatide Synthetic","moa":"GLP-1 receptor||Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Ingrid Jazet","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Ingrid Jazet"},{"orgOrder":0,"company":"Ethicon","sponsor":"Ali Aminian","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethicon \/ Ali Aminian","highestDevelopmentStatusID":"11","companyTruncated":"Ethicon \/ Ali Aminian"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Jody Dushay","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Jody Dushay","highestDevelopmentStatusID":"11","companyTruncated":"AstraZeneca \/ Jody Dushay"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sodium Deoxycholate","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Goldman, Butterwick, Fitzpatrick and Groff","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Goldman, Butterwick, Fitzpatrick and Groff"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
Sodium Deoxycholate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Weight Loss.
Details :
Bupropion HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Obesity.
Details :
Naltrexone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Obesity.
Details :
Bupropion is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Obesity.
Sponsor :
London Health Sciences Centre Research Institute (Lawson) | Queen Elizabeth II Health Sciences Centre | St. Michael's Hospital (Toronto, Canada)
Sponsor :
London Health Sciences Centre Research Institute (Lawson) | Queen Elizabeth II Health Sciences Centre | St. Michael's Hospital (Toronto, Canada)
Reset All
